Generic Name and Formulations:
Hydroquinone 4%, fluocinolone acetonide 0.01%, tretinoin 0.05%; crm; contains sulfites, parabens.
Galderma Laboratories, Inc.
Indications for TRI-LUMA:
Short-term intermittent treatment of moderate to severe melasma of the face, with measures for sun avoidance including sunscreen use (SPF 30).
Clean (use a mild, soap-free cleanser) and dry skin. Apply a thin film to affected area(s) and to ½ inch of surrounding normal skin once daily, at least 30 minutes before bedtime.
Do not occlude or use on eczema or sunburned skin. Avoid eyes, ears, mouth, angle of nose, mucous membranes, sun, UV light. Skin types V and VI (possible undesirable excessive bleaching). Discontinue if ochronosis, chemical irritation, hypersensitivity, or HPA axis suppression occurs. Increased irritation in extreme weather. Elderly. Pregnancy (Cat.C), nursing mothers: consider delaying use until after pregnancy/nursing.
Skin depigmenting agent + topical steroid + retinoid.
Avoid photosensitizers, topical irritants, and drying agents.
Local irritation (erythema, peeling, burning, dryness, pruritus), acne, paresthesia, telangiectasia, hyperesthesia, folliculitis, dermatitis, secondary infection, hypertrichosis, skin atrophy, striae, miliaria, HPA axis suppression.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)